Published
June 20, 2026
Updated
November 7, 2026
The court granted final approval of Teva's $35 million QVAR inhaler antitrust settlement on August 5, 2026. Claims closed July 31, 2026, and no payment date has been announced.
Current Status
Claims are closed. The deadline was July 31, 2026. Judge Nathaniel M. Gorton held the fairness hearing on August 5, 2026 and the same day entered the Order Granting Final Approval and Judgment (ECF 219), finding that no objections had been submitted, and the Order Awarding Attorney Fees (ECF 220). No payment date had been announced as of November 7, 2026.What Changed Recently
The August 5, 2026 fee order awarded Class Counsel $11,550,000 in attorneys' fees (33% of the $35 million fund) and $666,412.26 in litigation expenses, and approved service awards of $20,000 for each of the four class representatives, less than the $25,000 each described on the settlement website. Under the order, the expenses and 57% of the fee are paid on entry, and the remaining 43% of the fee is payable on or about March 31, 2027, coinciding with Teva's final installment payment into the Settlement Fund.What Is the QVAR Antitrust Settlement About?
Teva has agreed to a $35 million class action settlement to resolve antitrust claims over its QVAR and QVAR RediHaler asthma inhalers. The end-payor lawsuit alleges that Teva used a combination of product reformulations, strategic patent listings in the FDA's Orange Book, and related litigation to block or delay lower-cost generic versions of QVAR from reaching the market. When generics are kept off the market, consumers and insurers have no cheaper alternative and end up paying brand-name prices longer than they otherwise would. Teva denies the allegations and is settling without admitting any wrongdoing or liability.The case is captioned Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al., No. 1:23-cv-11131-NMG, in the U.S. District Court for the District of Massachusetts before Judge Nathaniel M. Gorton. The court granted preliminary approval in April 2026, the claim deadline was July 31, 2026, and the court granted final approval on August 5, 2026. For the latest case-status and procedural updates, see our QVAR settlement news update.
Status
Final Approval Granted — Payments Pending
final approval granted August 5, 2026 · no payment date announced
Claim Deadline
July 31, 2026 (Closed)
final approval hearing held August 5, 2026
Settlement Fund
$35 Million
pro rata cash · plus Teva's reported agreement to withdraw certain QVAR patents from the FDA Orange Book
Proof Required
Yes
proof of purchase is required for consumer claims — the form could be submitted first, but the administrator requests records (pharmacy/insurer records, EOBs, prescription history, receipts), and claims without adequate documentation may be audited, reduced, or rejected · third-party payors must submit transaction data
Who Qualifies for the QVAR Settlement?
You may qualify if you purchased, paid for, or were reimbursed for QVAR or QVAR RediHaler asthma inhalers between January 1, 2015 and July 31, 2025, and you lived in one of the eligible states. The settlement class covers two groups:• Individual consumers — people who bought QVAR out of pocket or through an insurance copay.
• Third-party payors — insurers, health plans, and other entities that paid for or reimbursed QVAR prescriptions for their members.
The class covers 41 states plus Washington, DC. The full list of eligible states is published in the official long-form notice on the settlement website. End-payor antitrust classes generally track the state laws that allow indirect purchasers to recover, so a handful of states without such laws are not included. If your state is not on the official list, you would not be part of this settlement class. Excluded from the class are the defendants and their affiliates, government entities, and class members who validly opt out.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
How Much Can You Get?
Individual payout amounts have not been announced. The total settlement fund is $35 million. The court awarded $11,550,000 in attorneys' fees, $666,412.26 in litigation expenses and $20,000 service awards for each of the four class representatives; the remainder forms the net fund before administration costs and other court-approved deductions.Payments are distributed pro rata, so each claimant's share depends on:
• The total number of valid claims filed.
• How much you spent on QVAR during the class period.
• How much purchase documentation you submit — proof of purchase is required for consumer claims, and better-documented claims receive a larger share.
Because the class spans roughly ten years and 41 states, individual amounts will vary widely. People who filled QVAR prescriptions frequently and over many years will generally receive more than someone who bought a single inhaler.
Do You Need Proof of Purchase?
Yes. Proof of purchase is required for consumer claims. The online claim form could be submitted without attaching documentation, but the Claims Administrator then requests supporting records, and a claim without adequate documentation may be audited, reduced, or rejected. No administrator-issued Claim ID or PIN gated the form, so class members who never received a mailed or emailed notice could file — but they need records to substantiate the claim. Accepted records include:• Pharmacy receipts or printouts showing the QVAR prescription and what you paid.
• Insurance Explanation of Benefits (EOB) statements listing QVAR prescription claims.
• Prescription history printouts from your pharmacy — most pharmacies will print or email a multi-year history on request.
• HSA or FSA statements showing QVAR purchases reimbursed through pre-tax accounts.
• A doctor's note or prescription records confirming a QVAR or QVAR RediHaler prescription.
• Receipts, credit-card statements, or checkbook entries showing a qualifying QVAR purchase.
Third-party payors file a separate claim and must substantiate their reimbursement data (typically through pharmacy claims records).
How QVAR Settlement Claims Were Filed
The claim window closed July 31, 2026. Claims could be filed two ways, both with the same deadline.Method 1: Online. Claimants completed the online claim form on the official settlement website at QVARAntitrustSettlement.com, with proof of purchase required for consumer claims; the administrator requests records from claimants who did not attach them up front.
Method 2: U.S. mail. Printable claim forms had to be postmarked no later than July 31, 2026.
Questions about a submitted claim go to the administrator through the contact form on the official website, not a third-party "filing service."
Why the Orange Book Matters in This Case
The FDA's "Orange Book" is a federal database that lists patents tied to approved drugs. A generic applicant generally has to navigate around any Orange-Book-listed patent before the FDA will approve its version, so a brand-name manufacturer can use Orange Book listings to slow generic competition. The QVAR lawsuit alleges Teva listed patents that should not have been there and used them, along with product changes, to keep cheaper generic inhalers off the market. The Federal Trade Commission has previously scrutinized some of these same QVAR-related Orange Book listings.Beyond the $35 million cash fund, Teva reportedly agreed to withdraw certain QVAR-related patents from the Orange Book — a step that could make it easier for generic QVAR to reach the market in the future.
Key QVAR Settlement Deadlines
• Claim deadline: July 31, 2026 (online or postmarked by mail) — closed.
• Class period covered: January 1, 2015 to July 31, 2025.
• Final Approval (fairness) hearing: held August 5, 2026 before Judge Nathaniel M. Gorton, U.S. District Court for the District of Massachusetts (Boston).
• Final approval: Order Granting Final Approval and Judgment entered August 5, 2026 (ECF 219).
What Happens Next
Distribution to approved claimants follows once the judgment becomes final and any appeals are resolved. The fee order ties the last part of Class Counsel's fee to Teva's final installment payment into the Settlement Fund, on or about March 31, 2027. No payment date for class members had been announced as of November 7, 2026, and any schedule will be posted on the official settlement website.Watch Out for QVAR Settlement Scams
Newly launched settlement claim forms attract scammers. A few common-sense rules:• Never pay a fee. Legitimate class action settlements never require an activation, processing, or "release" fee to file a claim or receive a payment.
• Never share your full Social Security number, bank password, or card number with anyone claiming to handle your QVAR claim by phone, text, or email.
• Use the official website only: QVARAntitrustSettlement.com. Be cautious of any email or text linking to a "QVAR settlement" page from a different domain.
Other Pharmaceutical Antitrust Settlements
QVAR is one of several pharmaceutical antitrust and pay-for-delay cases moving through the courts. Being in one settlement does not affect your eligibility for any other unrelated case.• Tracleer (Bosentan) Pay-for-Delay Settlement — a $65 million end-payer settlement over alleged delayed generic competition for the pulmonary-hypertension drug Tracleer (third-party payors only).
• Teva, Granules & Heritage Metformin Settlement — a $5.55 million settlement covering U.S. buyers of certain recalled generic metformin (July 2015 – June 2020).
• OCA database of open class action settlements — the full list of active consumer cases you can still claim.
Official Settlement Website: QVARAntitrustSettlement.com
Visit Official Site
Frequently Asked Questions About the QVAR Settlement
Who qualifies for the QVAR antitrust settlement?
Consumers and third-party payors who purchased, paid for, or reimbursed for QVAR or QVAR RediHaler asthma inhalers between January 1, 2015 and July 31, 2025 in one of the 41 eligible states plus Washington, DC. The full state list is on the official settlement website.
Is the QVAR settlement claim deadline still open?
The claim filing deadline was July 31, 2026, and the claim window is closed. Judge Nathaniel M. Gorton of the U.S. District Court for the District of Massachusetts held the Final Approval (fairness) hearing on August 5, 2026 and the same day entered the Order Granting Final Approval and Judgment (ECF 219) and the Order Awarding Attorney Fees (ECF 220).
Do I need proof of purchase to file a QVAR claim?
Yes — proof of purchase is required for consumer claims. You can submit the form first, but the Claims Administrator will then request supporting records (pharmacy or insurer records, a doctor's note or prescription records, EOBs, receipts, credit-card statements, or checkbook entries), and a claim without adequate documentation may be audited, reduced, or rejected. There is no administrator-issued Claim ID or PIN required to file.
How much could each person get from the QVAR settlement?
Individual payout amounts have not been announced. The total settlement fund is $35 million. On August 5, 2026, the court awarded Class Counsel $11,550,000 in attorneys' fees (33% of the fund) and $666,412.26 in litigation expenses, and approved service awards of $20,000 for each of the four class representatives; the remainder forms the net fund before administration costs and other deductions. Each claimant's share is distributed pro rata and depends on the total number of valid claims, how much each claimant spent on QVAR during the class period, and whether proof of purchase was submitted. Frequent, long-term QVAR buyers will generally receive more than someone who filled a single prescription.
What did Teva allegedly do wrong with QVAR?
The lawsuit alleges Teva used product reformulations, strategic Orange Book patent listings, and related litigation to delay generic QVAR competition, keeping prices high. Teva denies wrongdoing and settled to avoid further litigation.
When will QVAR settlement payments be sent?
No payment date had been announced as of November 7, 2026. The court granted final approval on August 5, 2026. Distribution to approved claimants follows once the judgment becomes final and any appeals are resolved, and any payment schedule will be posted on the official settlement website.
Sources
• Official Settlement Website: QVARAntitrustSettlement.com• Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al., No. 1:23-cv-11131-NMG, U.S. District Court for the District of Massachusetts (Hon. Nathaniel M. Gorton)
• Reuters, "Teva agrees to pay $35 million to settle asthma inhaler antitrust lawsuit" (October 2025)
• Long-Form Notice of Proposed Class Action Settlement and Settlement Claim Form
• Order Granting Final Approval and Judgment (ECF 219) and Order Awarding Attorney Fees (ECF 220), both entered August 5, 2026: QVARAntitrustSettlement.com Court Documents
• FDA: Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book)
• FTC: Health Care and Pharmaceutical Competition
Filing Class Action Settlement Claims
Please submit only truthful information on any claim. False or fraudulent claims can be rejected and may carry penalties. If you are not sure whether you qualify, review the eligibility information at QVARAntitrustSettlement.com. OpenClassActions.com is a consumer news site and is not the settlement administrator, class counsel, or a law firm, and we do not process or decide claims.
For more class actions keep scrolling below.
Settlement Amount
$35,000,000
Case Title
Iron Workers District Council of New England Health and Welfare Fund, et al. v. Teva Pharmaceutical Industries Ltd., et al.
Case Number
1:23-cv-11131-NMG
Court
U.S. District Court, District of Massachusetts
Final Approval Hearing
Held August 5, 2026 · final approval granted August 5, 2026
Judge Nathaniel M. Gorton · Order Granting Final Approval and Judgment, ECF 219
Administrator
A.B. Data, Ltd.
Official Website
QVAR Antitrust Settlement.com
